Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men

Bhasin, 1992, Clinical review 34: androgen treatment of hypogonadal men, J. Clin. Endocrinol. Metab., 74, 1221, 10.1210/jc.74.6.1221 Meikle, 1996, Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site—a clinical research center study, J. Clin. Endocrinol. Metab., 81, 1832, 10.1210/jc.81.5.1832 Snyder, 1980, Treatment of male hypogonadism with testosterone enanthate, J. Clin. Endocrinol. Metab., 51, 1335, 10.1210/jcem-51-6-1335 Wilson, 1980, The use and misuse of androgens, Metabolism, 29, 1278, 10.1016/0026-0495(80)90159-6 Burris, 1992, A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men, J. Androl., 13, 297 Nieschlag, 1996, Testoterone therapy, vol. 15, 297 Cunningham, 1989, Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels, JAMA, 261, 2525, 10.1001/jama.261.17.2525 Meikle, 1992, Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men, J. Clin. Endocrinol. Metab., 74, 623, 10.1210/jc.74.3.623 Wang, 2000, Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men, J. Clin. Endocrinol. Metab., 85, 2839, 10.1210/jc.85.8.2839 Fiet, 2001, Development of a sensitive and specific new plasma 4-androstene-3,17-dione time-resolved fluoroimmuno-assay (TR-FIA), Steroids, 66, 609, 10.1016/S0039-128X(00)00240-3 Fiet, 2004, Development of a highly sensitive and specific new testosterone time-resolved fluoroimmuno-assay in human serum, Steroids, 69, 461, 10.1016/j.steroids.2004.04.008 Heinemann, 1999, A new “aging males symptoms” rating scales, Aging Male, 2, 105, 10.3109/13685539909003173 Marquis, 2001, Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia, Value Health, 4, 335, 10.1046/j.1524-4733.2001.44021.x Food and Drug Administration, Centre for drug evaluation and research, Guidance for industry, Skin irritation and sensitization testing of generic transdermal drug products, 1999. Salehian, 1995, Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate—a clinical research center study, J. Clin. Endocrinol. Metab., 80, 3567, 10.1210/jc.80.12.3567 Dobs, 1999, Pharmacokinetics efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men, J. Clin. Endocrinol. Metab., 84, 3469, 10.1210/jc.84.10.3469 Mazer, 1992, Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men, J. Control. Release, 19, 347, 10.1016/0168-3659(92)90089-A Giton, 2007, Determination of bioavailable testosterone (non-sex hormone-binding globulin [SHBG]-bound testosterone) in a population of healthy French men: influence of androsenediol on tesosterone binding to SHBG, Clin. Chem., 53, 2160, 10.1373/clinchem.2007.087312 Skakkebaek, 1981, Androgen replacement with oral testosterone undecanoate in hypogonodal men: a double blind controlled study, Clin. Endocrinol., 14, 49, 10.1111/j.1365-2265.1981.tb00364.x Behre, 1999, Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years, Clin. Endocrinol., 50, 629, 10.1046/j.1365-2265.1999.00705.x Ahmed, 1988, Transdermal testosterone therapy in the treatment of male hypogonadism, J. Clin. Endocrinol. Metab., 66, 546, 10.1210/jcem-66-3-546 Jockenhövel, 2002, Practical aspects of testosterone substitution, Aging Male, 5, 21 Behre, 1994, Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls, Clin. Endocrinol., 40, 341, 10.1111/j.1365-2265.1994.tb03929.x Ozata, 1997, Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism, Endocr. J., 44, 719, 10.1507/endocrj.44.719 Tenover, 1992, Effects of testosterone supplementation in the aging male, J. Clin. Endocrinol. Metab., 75, 1092, 10.1210/jc.75.4.1092 Bhasin, 2006, Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline, J. Clin. Endocrinol. Metab., 91, 1995, 10.1210/jc.2005-2847 Arver, 1996, Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system, J. Urol., 155, 1604, 10.1016/S0022-5347(01)66141-X T'Sjoen, 2003, Perception of males’ aging symptoms, health and well-being in elderly community dwelling men is not related to circulating androgen levels, Psychoneuroendocrinology, 1 Snyder, 2000, Effects of testosterone replacement in hypogonadal men, J. Clin. Endocrinol. Metab., 85, 2670, 10.1210/jc.85.8.2670